RICHMOND, CA - Media OutReach - May 6, 2019 - Ekso Bionics Holdings,Inc. (NASDAQ: EKSO), an industry leader in exoskeleton technology for medicaland industrial use, today announced that the National University Health System(NUHS) in Singapore has adopted three EksoGT exoskeletons for a groundbreakingclinical study. NUHS is one of the first national health systems in Asia tostudy how advanced exoskeleton technology can improve mobility andrehabilitation outcomes, and the first to study it acrossthe entire continuum of care.

Photograph courtesy of Ekso Bionics

The ImprovingMobility via Exoskeletons (iMOVE) program, supported byTemasek Foundation and Trailblazer Foundation Limited, will study patientoutcomes and assess the viability and potential for scaling-up the use ofrobotic exoskeletons across the continuum of rehabilitation care from hospitalto community.  The study will focus on patientssuffering from stroke and spinal cord injuries, especially for the elderly.  The three EksoGT devices will be used atmultiple NUHS partner sites including Alexandra Hospital, NTUC Health, StLuke's Eldercare, St Luke's Hospital, and Stroke Support Station.

The iMOVE program was inaugurated today by Mr. Chan Heng Kee, PermanentSecretary of Ministry of Health, together with Professor John Wong Eu Li, ChiefExecutive of National University Hospital System and Mr. Richard Magnus,Chairman of Temasek Foundation. 

"We are delighted to be part of a program thatwill facilitate greater treatment accessibility in Singapore. Globally 15 million people suffer from a stroke every year; Asia ismore than half the world's population with a rapidly aging population in manycountries.  With aging, mobility becomesa big challenge.  The core mission of Ekso is to help peoplere-learn how to stand and walk after a stroke or spinal cord injury. We wantthe EksoGT systems to be widely accessible to people who never thought theycould walk or stand up again," commented Ms. LimChwee Foon, President, Asia Pacific, Ekso Bionics. "This will serve as a solidplatform for our growth in Asia."

With Ekso Bionics' recent expansion plan inAsia Pacific, EksoGTs are now deployed in Singapore, Hong Kong, and Australia. Todate, EksoGT has helped patients take more than 100 million steps in over 260 rehabilitationinstitutions around the world.

About EksoGT

EksoGT is the first exoskeleton cleared by theFDA for use with stroke and spinal cord injuries from L5 to C7. In Europe, theCE-Mark cleared EksoGT allows us to work with patients impacted by allneurological conditions and lower limb weakness. The EksoGT with SmartAssistsoftware is the only exoskeleton available for rehabilitation institutions thatcan provide adaptive amounts of power to either side of a patient's body,challenging the patient as they progress through their continuum of care. Thesuit's patented technology provides the ability to mobilize patients earlier,more frequently, and with a greater number of high intensity steps. To date, thisdevice has helped patients take 100 million steps in over 260 rehabilitationinstitutions around the world.

About Ekso Bionics®

Ekso Bionics^® is a leadingdeveloper of exoskeleton solutions that amplify human potential by supportingor enhancing strength, endurance and mobility across medical and industrialapplications. Founded in 2005, the company continues to build upon itsunparalleled expertise to design some of the most cutting-edge, innovativewearable robots available on the market. Ekso Bionics is the only exoskeletoncompany to offer technologies that range from helping those with paralysis tostand up and walk, to enhancing human capabilities on job sites across theglobe. The company is headquartered in the Bay Area and is listed on the NasdaqCapital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Forward-Looking Statements